{
    "Trade/Device Name(s)": [
        "BD Phoenix Automated Microbiology System - GN Ciprofloxacin (0.0156-4 \u03bcg/mL)",
        "BD Phoenix Automated Microbiology System \u2013 GN Ciprofloxacin (0.0156-4 \u03bcg/mL)"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K233986",
    "Predicate Device Reference 510(k) Number(s)": [
        "K060217"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON"
    ],
    "Summary Letter Date": "December 15, 2023",
    "Summary Letter Received Date": "December 18, 2023",
    "Submission Date": "March 15, 2024",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Ciprofloxacin"
    ],
    "Specimen Type(s)": [
        "Isolated bacterial colonies from pure culture"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Phoenix Automated Microbiology System",
        "BD PhoenixSpec Nephelometer",
        "BD Phoenix AP Instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Broth-based microdilution",
        "Colorimetric oxidation-reduction (redox indicator)",
        "Automated growth-based detection"
    ],
    "Methodologies": [
        "Minimal inhibitory concentration (MIC) determination",
        "Antimicrobial susceptibility testing"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Panel",
        "Automated system",
        "Software"
    ],
    "Document Summary": "FDA 510(k) summary for BD Phoenix Automated Microbiology System GN Ciprofloxacin panel (0.0156-4 \u03bcg/mL) for automated antimicrobial susceptibility testing of Gram-negative bacteria.",
    "Indications for Use Summary": "Intended for in vitro quantitative determination of antimicrobial susceptibility by minimal inhibitory concentration (MIC) of most Gram-negative aerobic and facultative anaerobic bacteria isolates from pure culture, including Enterobacteriaceae, non-Enterobacteriaceae, and most Gram-positive isolates of Staphylococcus, Enterococcus, and Streptococcus.",
    "fda_folder": "Microbiology"
}